Disease · HP_0005268
Miscarriage
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Miscarriage. Diseases, record HP_0005268. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0005268
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Miscarriage
- Open Targets ID
- HP_0005268
- Other names
- Early fetal demise, Early foetal demise, Spontaneous abortion
- Highest stage of its drugs
- Phase 3, for 5 of its 18 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs18
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MISOPROSTOL | CHEMBL606 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| CHORIOGONADOTROPIN ALFA | CHEMBL1201464 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| GONADOTROPIN, CHORIONIC | CHEMBL1201509 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NADROPARIN CALCIUM | CHEMBL2109204 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESTRADIOL | CHEMBL135 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DINOPROSTONE | CHEMBL548 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEMEPROST | CHEMBL1908315 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ISOSORBIDE MONONITRATE | CHEMBL1311 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 18
See all 18 drugsTargets68
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PGR | Progesterone receptor | 3 | Progesterone receptor agonist; Progesterone receptor antagonist | Unknown | https://conductscience.org/library/genes/5241 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor alpha agonist | Phase 2/3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| LHCGR | Lutropin-choriogonadotropic hormone receptor | 2 | Luteinizing hormone/Choriogonadotropin receptor agonist | Phase 3 | https://conductscience.org/library/genes/3973 | Drugs and targets |
| PTGER3 | Prostaglandin E2 receptor | 2 | Prostaglandin E2 receptor agonist; Prostanoid EP3 receptor agonist | Phase 3 | https://conductscience.org/library/genes/5733 | Drugs and targets |
| SERPINC1 | Antithrombin-III | 2 | Antithrombin-III activator | Phase 3 | https://conductscience.org/library/genes/462 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 3 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 3 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| CYP19A1 | Aromatase | 1 | Cytochrome P450 19A1 inhibitor | Unknown | https://conductscience.org/library/genes/1588 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Phase 3 | https://conductscience.org/library/genes/2820 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2982 | Drugs and targets |
1 to 10 of 68
See all 68 targetsTrials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00835731 | Misoprostol Versus Dilapan-S for Cervical Preparation | Not applicable | 125 | 2014-01-07 | Cervical Ripening | MISOPROSTOL | Its record names the disease | ClinicalTrials.gov |
| NCT06733727 | Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage | Not applicable | 884 | Silent Miscarriage | LETROZOLE, MIFEPRISTONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03740568 | Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes. | Not applicable | 598 | Infertility, Progesterone, Frozen Embryo Transfer, Euploid Embryo Transfer, Pregnancy Outcome, Artificial Cycle, Ongoing Pregnancy | PROGESTERONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02706470 | Use of Cyclosporin A for the Treatment of Recurrent Miscarriage | Phase 2/3 | 384 | Miscarriage, Recurrent | CYCLOSPORINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00994812 | The Effects of Metformin on Pregnancy and Miscarriage Rates in Polycystic Ovary Syndrome (PCOS) | Phase 3 | 326 | Polycystic Ovary Syndrome, Miscarriage, Infertility, Toxemia, Gestational Diabetes | METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01019655 | Heparin for Pregnant Women With Thrombophilia | Phase 3 | 300 | Pregnancy and Thrombophilia | NADROPARIN CALCIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT03479879 | Estradiol Pretreatment With Misoprostol in Second Trimester Miscarriage | Phase 2/3 | 200 | Miscarriage | ESTRADIOL, MISOPROSTOL | Its record names the disease | ClinicalTrials.gov | |
| NCT03487354 | Medical Abortion With Single Daily Dose of Misoprostol | Phase 2/3 | 200 | Miscarriage | MISOPROSTOL | Its record names the disease | ClinicalTrials.gov | |
| NCT05088720 | Misoprostol for Management of Women With an Incomplete Miscarriage | Not applicable | 200 | Miscarriage | MISOPROSTOL | Its record names the disease | ClinicalTrials.gov | |
| NCT01033903 | Optimal Treatment of Miscarriage | Not applicable | 190 | Abortion, Spontaneous | MISOPROSTOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Misoprostol vs Synthetic Osmotic Dilator: Number of Patients for Whom Physician Was Able to Complete Dilation and Evacuation Procedure on First Attempt | 62 of 62 | 60 of 60 | 122 | NCT00835731 | Trial comparisons |
| Misoprostol vs Synthetic Osmotic Dilator: serious adverse events | 0 of 62 | 0 of 60 | 122 | NCT00835731 | Trial comparisons |
Papers from its trials13
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 34061352 | DERIVED | 2 | PubMed |
| 33779986 | DERIVED | 1 | PubMed |
| 33686413 | DERIVED | 1 | PubMed |
| 33615468 | DERIVED | 1 | PubMed |
| 32358837 | DERIVED | 1 | PubMed |
| 31227287 | DERIVED | 1 | PubMed |
| 29626233 | DERIVED | 1 | PubMed |
| 29072372 | DERIVED | 1 | PubMed |
| 23743471 | DERIVED | 1 | PubMed |
| 23150927 | DERIVED | 1 | PubMed |
1 to 10 of 13
See all 13 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0005268
GET https://conductscience.org/api/diseases/v1/HP_0005268/targets?page=2